236 results
8-K
EX-99.1
MRK
Merck & Co Inc
25 Apr 24
Merck Announces First-Quarter 2024 Financial Results
6:41am
impact of foreign exchange.
Research and development (R&D) expenses were $4.0 billion in the first quarter of 2024 compared with $4.3 billion … costs, reflecting the prioritization of spending on key growth products, and the favorable impact of foreign exchange.
- 6 -
Non-GAAP R&D expenses
8-K
EX-99.1
MRK
Merck & Co Inc
1 Feb 24
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
6:39am
EPS excludes acquisition- and divestiture-related costs, including pretax intangible asset impairment research and development (R&D) charges of $779 … consideration. R&D expenses include intangible asset impairment charges of $779 million in both the fourth quarter and full year of 2023 related
8-K
EX-99.1
w2yv1ohphfy4817gpt0q
26 Oct 23
Merck Announces Third-Quarter 2023 Financial Results
6:38am
8-K
EX-99.1
hgv1sijzbm
1 Aug 23
Merck Announces Second-Quarter 2023 Financial Results
6:46am
8-K
EX-99.1
iw114sql4
27 Apr 23
Merck Announces First-Quarter 2023 Financial Results
6:43am
PX14A6G
rr5nr02
21 Apr 23
Letter to shareholders
7:39pm
PX14A6G
tf9euueq
19 Apr 23
Letter to shareholders
4:04pm
8-K
EX-99.1
tnggukbpl2 yo1ohs
27 Oct 22
Merck Announces Third-Quarter 2022 Financial Results
6:38am
8-K
EX-99.1
eebqk8 z1
28 Jul 22
Merck Announces Second-Quarter 2022 Financial Results
6:36am
PX14A6G
70smv3nzpo npgv
13 May 22
Letter to shareholders
2:32pm